Cybin (CYBN) announced additional strategic partnership agreements, bringing the total to 18 clinical sites engaged to advance Cybin’s multinational Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD. The APPROACH study is expected to include approximately 45 clinical sites. Cybin initiated the SPA program earlier this year with Segal Trials, a leading clinical research network located in South Florida. Each of the 18 U.S.-based SPA sites bring decades of clinical experience and a commitment to excellence to support and expedite the Company’s Phase 3 PARADIGM program.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Partners with Osmind to Boost Commercial Readiness for Psychiatry Programs
- Psychedelic: Exclusive talk with retreat provider ONE Retreats
- Psychedelic: Exclusive talk with biotech company Clearmind Medicine
- Psychedelic: atai Life Sciences, NRx report quarterly results
- Sunrun, HubSpot, Rocket, Summit, Cybin: Trending by Analysts
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue